Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
- Status
- RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)
- Status
- RECRUITING
- Phase
- PHASE1
Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)
- Status
- RECRUITING
- Phase
- N/A
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer.
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
- Status
- RECRUITING
- Phase
- PHASE2
BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
- Status
- RECRUITING
- Phase
- PHASE2
Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)
- Status
- RECRUITING
- Phase
- EARLY_PHASE1
PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2